Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:DMAC NASDAQ:EDIT NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.95-0.3%$3.79$2.90▼$11.16$349.50M0.072.80 million shs1.93 million shsDMACDiaMedica Therapeutics$6.88+1.8%$6.58$3.19▼$7.49$349.42M1.4244,700 shs309,492 shsEDITEditas Medicine$3.72+1.9%$3.18$0.91▼$4.54$328.21M2.183.19 million shs1.62 million shsSTROSutro Biopharma$1.05-0.9%$0.91$0.52▼$4.60$89.86M1.611.52 million shs671,471 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.54%+1.80%+4.49%-2.94%-41.07%DMACDiaMedica Therapeutics+0.75%+1.20%-1.46%+33.86%+54.34%EDITEditas Medicine+2.24%-7.83%+21.26%+15.87%+13.71%STROSutro Biopharma-8.62%+20.36%+27.96%+19.48%-69.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.95-0.3%$3.79$2.90▼$11.16$349.50M0.072.80 million shs1.93 million shsDMACDiaMedica Therapeutics$6.88+1.8%$6.58$3.19▼$7.49$349.42M1.4244,700 shs309,492 shsEDITEditas Medicine$3.72+1.9%$3.18$0.91▼$4.54$328.21M2.183.19 million shs1.62 million shsSTROSutro Biopharma$1.05-0.9%$0.91$0.52▼$4.60$89.86M1.611.52 million shs671,471 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.54%+1.80%+4.49%-2.94%-41.07%DMACDiaMedica Therapeutics+0.75%+1.20%-1.46%+33.86%+54.34%EDITEditas Medicine+2.24%-7.83%+21.26%+15.87%+13.71%STROSutro Biopharma-8.62%+20.36%+27.96%+19.48%-69.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.38Hold$17.40340.51% UpsideDMACDiaMedica Therapeutics 2.50Moderate Buy$12.3379.26% UpsideEDITEditas Medicine 2.14Hold$5.1037.10% UpsideSTROSutro Biopharma 2.00Hold$4.47325.40% UpsideCurrent Analyst Ratings BreakdownLatest STRO, DMAC, EDIT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ALTAltimmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025EDITEditas MedicineWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/20/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/10/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/8/2025ALTAltimmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025EDITEditas MedicineWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025STROSutro BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ALTAltimmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K17,431.35N/AN/A$1.74 per share2.27DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AEDITEditas Medicine$32.31M10.35N/AN/A$1.63 per share2.28STROSutro Biopharma$62.04M1.43N/AN/A$0.54 per share1.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)EDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)STROSutro Biopharma-$227.46M-$2.53N/AN/AN/A-201.32%-852.70%-58.67%11/12/2025 (Estimated)Latest STRO, DMAC, EDIT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025DMACDiaMedica Therapeutics-$0.15N/AN/AN/AN/AN/A11/12/2025Q3 2025STROSutro Biopharma-$0.39N/AN/AN/AN/AN/A11/11/2025Q3 2025ALTAltimmune-$0.29N/AN/AN/A$0.00 millionN/A11/3/2025Q3 2025EDITEditas Medicine-$0.38N/AN/AN/AN/AN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/7/2025Q2 2025STROSutro Biopharma-$0.39-$0.14+$0.25-$0.14$14.55 million$63.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44DMACDiaMedica TherapeuticsN/A7.557.55EDITEditas MedicineN/A2.772.77STROSutro BiopharmaN/A3.123.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%DMACDiaMedica Therapeutics10.12%EDITEditas Medicine71.90%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%DMACDiaMedica Therapeutics7.30%EDITEditas Medicine2.10%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionableEDITEditas Medicine23089.92 million88.03 millionOptionableSTROSutro Biopharma24084.77 million81.72 millionOptionableSTRO, DMAC, EDIT, and ALT HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Hold" by AnalystsOctober 19, 2025 | marketbeat.comInsider Buying: Sutro Biopharma (NASDAQ:STRO) Insider Buys 12,504 Shares of StockOctober 17, 2025 | marketbeat.comHans-Peter Gerber Purchases 17,000 Shares of Sutro Biopharma (NASDAQ:STRO) StockOctober 17, 2025 | marketbeat.comGregory Chow Acquires 19,750 Shares of Sutro Biopharma (NASDAQ:STRO) StockOctober 17, 2025 | marketbeat.comInsider Buying: Sutro Biopharma (NASDAQ:STRO) Director Acquires 50,000 Shares of StockOctober 17, 2025 | marketbeat.comDavid Pauling Purchases 12,504 Shares of Sutro Biopharma (NASDAQ:STRO) StockOctober 17, 2025 | insidertrades.comSutro Biopharma's (STRO) "Sell (E+)" Rating Reiterated at Weiss RatingsOctober 9, 2025 | marketbeat.comSutro Biopharma trims workforce again to extend cash runwayOctober 1, 2025 | thepharmaletter.comTSutro Makes Deeper Cuts To Extend Runway Into 2027, Reach Key Data ReadoutOctober 1, 2025 | biospace.comBSutro Biopharma announces restructuring, workforce reduction of about 33%September 29, 2025 | msn.comSutro Biopharma stock jumps after restructuring to extend cash runwaySeptember 29, 2025 | za.investing.comSutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key MilestonesSeptember 29, 2025 | globenewswire.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 24, 2025 | marketbeat.comSutro Biopharma price target lowered to $4 from $7 at JefferiesSeptember 9, 2025 | msn.comVaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal DiseaseSeptember 3, 2025 | quiverquant.comQSutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial CancersAugust 20, 2025 | msn.comSutro Biopharma (STRO) Gets a Buy from Truist FinancialAugust 14, 2025 | theglobeandmail.comSutro Biopharma price target lowered to $3 from $4 at Wells FargoAugust 12, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)August 9, 2025 | theglobeandmail.comSutro Biopharma, Inc.: Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 8, 2025 | finanznachrichten.deSutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue EstimatesAugust 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesOctober’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300By Sam Quirke | September 29, 2025JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall?By Leo Miller | October 19, 20253 Exceptional Stocks to Build Long-Term WealthBy Chris Markoch | October 6, 2025Copper Giant Freeport Slumps but Analysts See 33% UpsideBy Leo Miller | September 26, 2025STRO, DMAC, EDIT, and ALT Company DescriptionsAltimmune NASDAQ:ALT$3.95 -0.01 (-0.25%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.02 (+0.63%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.DiaMedica Therapeutics NASDAQ:DMAC$6.88 +0.12 (+1.78%) Closing price 04:00 PM EasternExtended Trading$6.86 -0.01 (-0.22%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Editas Medicine NASDAQ:EDIT$3.72 +0.07 (+1.92%) Closing price 04:00 PM EasternExtended Trading$3.74 +0.02 (+0.65%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Sutro Biopharma NASDAQ:STRO$1.05 -0.01 (-0.94%) Closing price 04:00 PM EasternExtended Trading$1.06 +0.01 (+0.95%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
